NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Molecular Partners AG (SW: MOLN)

 
MOLN Technical Analysis
5
As on 19th Nov 2025 MOLN STOCK Price closed @ 3.40 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.76 & Strong Sell for SHORT-TERM with Stoploss of 5.89 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MOLNSTOCK Price

Open 3.27 Change Price %
High 3.40 1 Day 0.09 2.72
Low 3.22 1 Week 0.11 3.34
Close 3.40 1 Month 0.40 13.33
Volume 13989 1 Year -0.35 -9.33
52 Week High 9.30 | 52 Week Low 2.75
 
SW Switzerland Most Active Stocks
CSGN 0.82 0.00%
CSGN 0.82 0.00%
UBSG 30.60 1.06%
UBSG 30.60 1.06%
NESN 79.42 0.20%
NESN 79.42 0.20%
ABBN 54.46 0.67%
ABBN 54.46 0.67%
NOVN 102.22 0.22%
NOVN 102.22 0.22%
 
SW Switzerland Top Gainers Stocks
CADN 0.03 50.00%
PRFN 0.03 50.00%
PRFN 0.03 50.00%
BLS 0.13 18.18%
BLS 0.13 18.18%
BLS 0.13 18.18%
NEWN 0.94 17.50%
CIE 0.21 16.67%
CIE 0.21 16.67%
CIE 0.21 16.67%
 
SW Switzerland Top Losers Stocks
AFP 1.00 -93.75%
AFP 1.00 -93.75%
AFP 1.00 -93.75%
MBTN 0.06 -14.29%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
CON 98.00 -12.35%
 
 
MOLN
Daily Charts
MOLN
Intraday Charts
Whats New @
Bazaartrend
MOLN
Free Analysis
 
MOLN Important Levels Intraday
RESISTANCE3.75
RESISTANCE3.64
RESISTANCE3.57
RESISTANCE3.50
SUPPORT3.30
SUPPORT3.23
SUPPORT3.16
SUPPORT3.05
 
MOLN Forecast November 2025
4th UP Forecast7.43
3rd UP Forecast6.14
2nd UP Forecast5.34
1st UP Forecast4.54
1st DOWN Forecast2.26
2nd DOWN Forecast1.46
3rd DOWN Forecast0.66
4th DOWN Forecast-0.63
 
MOLN Weekly Forecast
4th UP Forecast14.00
3rd UP Forecast10.60
2nd UP Forecast8.50
1st UP Forecast6.40
1st DOWN Forecast0.40
2nd DOWN Forecast-1.70
3rd DOWN Forecast-3.80
4th DOWN Forecast-7.20
 
MOLN Forecast2025
4th UP Forecast16.5
3rd UP Forecast12.3
2nd UP Forecast9.7
1st UP Forecast7.11
1st DOWN Forecast-0.31
2nd DOWN Forecast-2.9
3rd DOWN Forecast-5.5
4th DOWN Forecast-9.7
 
 
MOLN Other Details
Segment EQ
Market Capital 567939712.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
MOLN Address
MOLN
 
MOLN Latest News
 
Your Comments and Response on Molecular Partners AG
 
MOLN Business Profile
Molecular Partners AG operates as a clinical-stage biopharmaceutical company. It is developing Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration, as well as for diabetic macular edema; and MP0250 that binds and inhibit vascular endothelial growth factor and hepatocyte growth factor pathways, which restores clinical sensitivity to various standard-of-care therapies in multiple myeloma. The company is also developing MP0274 that is in Phase I clinical trials for HER2-positive solid tumors; MP0310, which is in Phase I clinical trials for immuno-oncology; MPO317, a tumor-localized immune agonist that activates immune cells in the tumor; and Peptide-MHC, a tumor-localized immune-cell agonist to attack tumors. It has strategic partnerships with Allergan, Inc. and Amgen SA; and collaboration with AGC Biologics to develop anti-COVID-19 DARPin program. Molecular Partners AG was founded in 2004 and is headquartered in Schlieren, Switzerland. Address: Wagistrasse 14, Schlieren, Switzerland, 8952
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service